Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | APLNR | P35414 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.45 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200836 | 0.87 | TAS2R14 (0.48) | LTA4HAPLNRACHETAS2R14BMP1 | |
| SCHEMBL30200646 | 0.86 | ALDH1A1 (0.50) | ALDH1A1APLNRBCHEACHETAS2R14 | |
| SCHEMBL30200719 | 0.85 | ALDH1A1 (0.49) | ALDH1A1APLNRBCHEACHETAS2R14 | |
| SCHEMBL25346196 | 0.81 | APLNR (0.55) | ALDH1A1APLNRTAS2R14HTTSMN1; SMN2 | |
| SCHEMBL6122068 | 0.78 | TRPM8 (0.48) | ALDH1A1LTA4HBMP1HTT | |
| SCHEMBL7003011 | 0.77 | BMP1 (0.73) | ALDH1A1BMP1 | |
| SCHEMBL7003868 | 0.76 | ALDH1A1 (0.59) | ALDH1A1TAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL7004788 | 0.76 | BMP1 (0.66) | ALDH1A1TAS2R14BMP1PTGESTAS2R8 | |
| SCHEMBL9833066 | 0.75 | ALDH1A1 (0.48) | ALDH1A1LTA4HBCHEACHEHTT | |
| SCHEMBL16235820 | 0.75 | APLNR (0.65) | APLNRTAS2R14BMP1PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ALDH1A1 4101/4885LTA4H 4382/4885APLNR 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.